Jones Financial Companies Lllp Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Jones Financial Companies Lllp lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 55.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,447 shares of the biopharmaceutical company’s stock after purchasing an additional 519 shares during the quarter. Jones Financial Companies Lllp’s holdings in Gilead Sciences were worth $117,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Tompkins Financial Corp raised its holdings in shares of Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares in the last quarter. Fortitude Family Office LLC bought a new position in Gilead Sciences during the 4th quarter worth approximately $29,000. Private Wealth Management Group LLC purchased a new position in Gilead Sciences in the 4th quarter worth approximately $29,000. Sachetta LLC bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $30,000. Finally, Rakuten Securities Inc. purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $63.88 on Thursday. The business has a fifty day moving average price of $67.02 and a 200-day moving average price of $73.86. The company has a market capitalization of $79.58 billion, a PE ratio of 177.44, a PEG ratio of 1.28 and a beta of 0.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94.

Gilead Sciences (NASDAQ:GILDGet Free Report) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the prior year, the company posted $1.37 earnings per share. The company’s quarterly revenue was up 5.3% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.82%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on GILD. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a research report on Wednesday, April 24th. Mizuho reduced their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Morgan Stanley dropped their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. UBS Group decreased their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $83.69.

Check Out Our Latest Report on GILD

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Articles

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.